[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69719931D1 - Verwendung von Acetylcystein zur Herstellung eines Arzneimittels zur Behandlung von chronischen Geschwüren - Google Patents

Verwendung von Acetylcystein zur Herstellung eines Arzneimittels zur Behandlung von chronischen Geschwüren

Info

Publication number
DE69719931D1
DE69719931D1 DE69719931T DE69719931T DE69719931D1 DE 69719931 D1 DE69719931 D1 DE 69719931D1 DE 69719931 T DE69719931 T DE 69719931T DE 69719931 T DE69719931 T DE 69719931T DE 69719931 D1 DE69719931 D1 DE 69719931D1
Authority
DE
Germany
Prior art keywords
treatment
ulcers
acetylcysteine
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69719931T
Other languages
English (en)
Other versions
DE69719931T2 (de
Inventor
Stephen Bloor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Medical Ltd
Original Assignee
Johnson and Johnson Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson and Johnson Medical Ltd filed Critical Johnson and Johnson Medical Ltd
Application granted granted Critical
Publication of DE69719931D1 publication Critical patent/DE69719931D1/de
Publication of DE69719931T2 publication Critical patent/DE69719931T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69719931T 1996-12-20 1997-12-19 Verwendung von Acetylcystein zur Herstellung eines Arzneimittels zur Behandlung von chronischen Geschwüren Expired - Lifetime DE69719931T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9626468A GB2320431B (en) 1996-12-20 1996-12-20 Compositions for the treatment of chronic wounds

Publications (2)

Publication Number Publication Date
DE69719931D1 true DE69719931D1 (de) 2003-04-24
DE69719931T2 DE69719931T2 (de) 2003-12-24

Family

ID=10804743

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69719931T Expired - Lifetime DE69719931T2 (de) 1996-12-20 1997-12-19 Verwendung von Acetylcystein zur Herstellung eines Arzneimittels zur Behandlung von chronischen Geschwüren

Country Status (11)

Country Link
US (1) US6166084A (de)
EP (1) EP0848951B1 (de)
JP (1) JPH10273438A (de)
AT (1) ATE234615T1 (de)
AU (1) AU726545B2 (de)
CA (1) CA2225202A1 (de)
CO (1) CO4930267A1 (de)
DE (1) DE69719931T2 (de)
GB (1) GB2320431B (de)
SG (1) SG63786A1 (de)
ZA (1) ZA9711467B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1312088B1 (it) * 1999-04-21 2002-04-04 Altergon Sa Cerotto per uso topico contenente eparina e diclofenac.
DE60117043T2 (de) * 2000-11-22 2006-07-13 Rxkinetix, Inc., Louisville Behandlung von mukositis
US6600057B2 (en) 2000-12-29 2003-07-29 Kimberly-Clark Worldwide, Inc. Matrix metalloproteinase inhibitors
DE10121255A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag Verwendung von alpha 1-Antichymotrypsin Polypeptiden oder diese kodierende Nukleinsäuren, oder einer ein ACT Polypeptid oder diese kodierende Nukleinsäure exprimierende Zelle, zur Behandlung und/oder Prävention von diabetes-assoziierten und/oder arteriellen schlecht heilenden Wunden und zur Identifizierung von pharmakologisch aktiven Substanzen
WO2003015808A1 (en) * 2001-08-16 2003-02-27 Hnat Thomas M Method and composition for treatment of wounds and burns
SE522979C2 (sv) * 2002-07-03 2004-03-23 Moelnlycke Health Care Ab Sårförband innefattande en icke-enzymatisk antioxidant
CA2529236A1 (en) * 2004-12-07 2006-06-07 Centre Des Technologies Textiles New antimicrobial material
WO2007137000A2 (en) * 2006-05-16 2007-11-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Combination cancer chemotherapy
US20090131303A1 (en) * 2007-11-16 2009-05-21 Bor-Shyue Hong Methods and compositions for treating dry eye
US20090177133A1 (en) * 2008-01-04 2009-07-09 Kristine Kieswetter Reduced pressure dressing coated with biomolecules
WO2010014306A1 (en) * 2008-07-28 2010-02-04 Tyco Healthcare Group Lp Antimicrobial and anticoagulant compositions and methods
GB2470040A (en) * 2009-05-06 2010-11-10 Systagenix Wound Man Ip Co Bv Wound dressing material comprising N-acetyl cysteine
US8765794B2 (en) * 2009-06-25 2014-07-01 Darlene McCord Compositions and methods for wound care
US9999702B2 (en) 2010-04-09 2018-06-19 Kci Licensing Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
US8632512B2 (en) 2010-04-09 2014-01-21 Kci Licensing, Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
EP2397125A1 (de) 2010-06-15 2011-12-21 Histocell, S.L. Antioxidationszusammensetzung
CA2849382C (en) 2010-09-22 2021-02-16 The Regents Of The University Of Colorado, A Body Corporate Therapeutic applications of smad7 for the treatment of oral mucositis
US8597264B2 (en) 2011-03-24 2013-12-03 Kci Licensing, Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
US10456448B2 (en) 2013-03-08 2019-10-29 The Regents Of The University Of Colorado, A Body Corporate PTD-SMAD7 therapeutics
EP3804742A1 (de) 2013-03-15 2021-04-14 3M Innovative Properties Company Wundheilende zusammensetzungen
EP3107905B1 (de) 2014-02-20 2018-09-19 University of Notre Dame du Lac Selektive matrix-metalloproteinaseinhibitoren
WO2016044844A1 (en) 2014-09-19 2016-03-24 University Of Notre Dame Du Lac Acceleration of diabetic wound healing
MX2017004520A (es) 2014-10-14 2018-03-15 Lynch Samuel Composiciones para tratar heridas.
WO2018140383A1 (en) * 2017-01-24 2018-08-02 Leal Jesus N-acetyle cysteine based compositions
US10292998B1 (en) 2018-08-07 2019-05-21 Ahad Mahootchi Compositions and methods for prevention and treatment of eye infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1154914A (en) * 1965-08-26 1969-06-11 Mead Johnson & Co Anti-Inflammatory Compositions and methods
ZA702518B (en) * 1969-04-18 1971-01-27 Bristol Myers Co Acetylcysteine for acne
US3749770A (en) * 1969-08-11 1973-07-31 Mead Johnson & Co Compositions containing zinc mercaptide n-acetylcysteine carboxylate salts
US4276284A (en) * 1971-07-26 1981-06-30 Brown Stuart I Prevention of collagenase induced disease by treatment with collagenase inhibitors
FR2519988B1 (fr) * 1982-01-20 1985-06-14 Refarmed Sa Derives thioliques de l'erythromycine a activite therapeutique, procede de preparation et produits pharmaceutiques dans lesquels ils apparaissent
IT1194117B (it) * 1981-11-20 1988-09-14 Isnardi Pietro & C Spa Derivati salicilici di n-acetilcisteina
US4414387A (en) * 1982-05-13 1983-11-08 Renato Broggi Cephapirin acetylcysteinate having antibacterial activity
GB8517301D0 (en) * 1985-07-09 1985-08-14 Salim A S M Synergistic biologically active substances
US4708965A (en) * 1985-09-16 1987-11-24 Morgan Lee R Method of treating herpes virus infections with N,N'-diacetylcystine and derivatives
US4724239A (en) * 1985-09-16 1988-02-09 Morgan Lee R Method of treating chemical ulcers with N,N'-diacetylcystine, N-acetyl homocysteine and N-acetyl cysteine
IL95393A0 (en) * 1989-08-18 1991-06-30 John Morris Co Odor-masked and stabilized compositions for treating keratinous tissue,skin conditions,and promoting wound healing
JPH11501611A (ja) * 1993-06-18 1999-02-09 アークチュラス、ファーマシューティカル、コーポレーション 過角化及びプロテアーゼによって媒介される疾患の治療のための方法
DE4328871A1 (de) * 1993-08-27 1995-03-02 Beiersdorf Ag Mittel gegen empfindliche, hyperreaktive Hautzustände, atopische Dermatiden, Pruritus, Psoriasis Prurigo, Photodermatosen und Ichthyosis

Also Published As

Publication number Publication date
CO4930267A1 (es) 2000-06-27
JPH10273438A (ja) 1998-10-13
EP0848951A1 (de) 1998-06-24
DE69719931T2 (de) 2003-12-24
GB2320431A8 (en) 1998-12-18
SG63786A1 (en) 1999-03-30
GB2320431B (en) 2000-08-30
CA2225202A1 (en) 1998-06-20
AU726545B2 (en) 2000-11-09
GB9626468D0 (en) 1997-02-05
EP0848951B1 (de) 2003-03-19
US6166084A (en) 2000-12-26
ZA9711467B (en) 1999-09-20
GB2320431A (en) 1998-06-24
ATE234615T1 (de) 2003-04-15
AU4838397A (en) 1998-06-25

Similar Documents

Publication Publication Date Title
DE69719931D1 (de) Verwendung von Acetylcystein zur Herstellung eines Arzneimittels zur Behandlung von chronischen Geschwüren
DE69207847D1 (de) Verwendung von Rapamycin zur Herstellung eines Arzneimittels zur Behandlung von Augenentzündungen
AR052921A1 (es) Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica
DE59109222D1 (de) Verwendung des Wirkstoffs Flupirtin zur Herstellung eines Arzneimittels zur Bekämpfung von Muskelverspannungen
FI971420A0 (fi) Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
DE69010162D1 (de) Zusammensetzung zur Behandlung von Entzündung.
DE69428325D1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen Derivaten zur Herstellung eines Medikaments zur Hemmung der Angiogenese und angiogene Krankheiten
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE68911891D1 (de) Verwendung von Acetyl-L-carnitin zur Behandlung von Katarakt, sowie pharmazeutische Zusammensetzungen für eine derartige Behandlung.
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
DE59605959D1 (de) Verwendung von Immunglobulin-Präparationen zur Herstellung eines Medikaments zur oralen Verabreichung zur Behandlung und Prophylaxe chronischer Schmerzzustände
ATE119770T1 (de) Verwendung von acetyl l-carnitin zur therapeutischen behandlung von coma.
RS52011B (sr) Nova primena derivata taksoida
DE69800859D1 (de) Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
DE69227583D1 (de) Arylmorpholine, herstellung und verwendung
ES2093357T3 (es) Metodo de tratamiento de la alopecia.
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
DE69106777D1 (de) Behandlung von intraokularem Druck mit einer ophthalmischen synergistischen Kombination.
ES2075272T5 (es) Composiciones dermatologicas conteniendo acido cis-urocanico.
DE69100171D1 (de) Synergistische kombination zur ophthalmischen verwendung.
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
SE9602262D0 (sv) New use of derivatives of cystine
ATE271867T1 (de) Behandlung der harninkontinenz und zusammenstellung dafür
DE59504374D1 (de) Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN